Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on September 13, 2021. The report details a material definitive agreement entered into on the same date regarding a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of unregistered common stock (PIPE).
- Shares Issued: 309,242 shares of Common Stock.
- Purchase Price: Approximately $776,197 aggregate.
- Price Per Share: $2.51 (a $0.01 premium to the Nasdaq Minimum Price).
- Use of Proceeds: Working capital and general corporate purposes.
- Insider Participation: CEO Lisa Conte and CFO Carol Lizak each invested approximately $20,000.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with certain investors. The shares were sold in reliance on exemptions under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. The Company agreed to file a registration statement on Form S-3 within 90 calendar days of closing to register the resale of these shares.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue outlook, or updated risk factors beyond the standard disclosures associated with the private placement. The primary focus is the execution of the capital raise to support working capital needs.
Key Facts for Investor Verification
- Verify the closing date of the Private Placement and the actual receipt of proceeds.
- Confirm the filing of the Form S-3 registration statement within the required 90-day window.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific covenants and investor rights.
- Monitor subsequent filings for the impact of the new share issuance on total outstanding shares and potential dilution.